Just because the S&P 500 hit a new all-time high doesn't mean all stocks are expensive.The S&P 500 just reached a new all-time high and the Dow Jones Industrial Average broke the 40,000 level for the first time ever. However, in this video, Fool.com contributors Matt Frankel, CFP®, and Tyler Crowe talk about two stocks they recently bought that could be excellent long-term opportunities.*Stock prices used were the morning prices of May 17, 2024. The video was published on May 18, 2024. ...

This fast-growing chipmaker has a lot of advantages. But there is one big risk investors should be aware of.If you want to bet on generative artificial intelligence (AI), there is still no better pick than Nvidia (NVDA 0.64%). The company dominates the market for cutting-edge AI data center chips. And unsurprisingly, shares have risen by a whopping 206% over the last 12 months alone. But can the bull run continue? Let's look at three reasons to continue buying Nvidia stock and one reason why it might be tim ...

This pharma giant just made a smart strategic acquisition.There are plenty of reasons to buy a leading biopharma business like AbbVie (ABBV -0.99%), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company.Though the area isn't traditionally in AbbVie's wheelhouse, there's reason to believe that its latest bet will turn out well for investors. Here's why.This new segment could be incredibly valuableOn May ...

Group 1: Market Overview - The stock market is experiencing significant growth, with the Nasdaq and S&P 500 reaching new record highs, indicating a bull market phase that is expected to last longer than bear markets [1][2] - Historical data shows that the average bull market lasts nearly nine years, while bear markets last approximately 1.4 years, suggesting ample time for investors to benefit from current market conditions [2] Group 2: Biotech Industry Potential - The biotech industry presents numerous investment opportunities, particularly for companies that have recently received product approvals, signaling strong growth potential [3] - Companies with solid long-term prospects are likely to provide returns that extend beyond the current bull market [2] Group 3: CRISPR Therapeutics - CRISPR Therapeutics has received regulatory approval for Casgevy, a treatment for sickle cell disease and beta thalassemia, marking the first approval of a CRISPR-based treatment [4][5] - The company has over 25 authorized treatment centers ready to launch Casgevy, with multiple patients already in the treatment process, indicating strong initial demand [5] - CRISPR is also developing a lighter conditioning treatment and in vivo gene editing of stem cells, which could broaden the application of its technology and enhance patient uptake [6] - The stock is currently trading lower than in previous years, presenting a buying opportunity for growth investors as the Casgevy launch progresses [7] Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in tumor infiltrating lymphocyte (TIL) treatments and has received approval for Amtagvi, its first commercialized TIL product for advanced melanoma [8][9] - The company reports that over 100 patients have enrolled for Amtagvi since its approval, with plans to establish 50 authorized treatment centers by the end of the month and over 70 by year-end [10] - Amtagvi has received reimbursement approvals from payers covering over 200 million people, enhancing accessibility for patients in need [11] - Iovance is also leveraging its technology across its pipeline, indicating potential for additional growth drivers in the future [12]

The company is striking new partnerships to extend its AI reach.International Business Machines (IBM 2.09%) has found its footing in the AI market by focusing on enterprise customers with complex requirements. The company's watsonx platform caters to companies and organizations that need to train, tune, and deploy AI applications while minding regulatory, legal, and other concerns.This strategy is going well for IBM so far. The company has a book of business related to watsonx and generative AI that tops $1 ...

Target's new membership has a lot of potential if Target makes the changes necessary to make it a must-have for shoppers.Target (TGT -0.59%) is trying to move into the membership business by leveraging its large base of credit card users and digital products. However, the company has failed to make the system efficient and delightful for consumers, undermining the strategy. In this video, Travis Hoium covers the mistakes Target is making and how they could be fixed.*Stock prices used were end-of-day prices ...

The cloud software giant still hasn't joined the four-comma club ... yet.Salesforce (CRM -1.15%) is one of the world's largest cloud software companies, but it's still much smaller (as measured by market cap) than Amazon, Microsoft, and Alphabet  -- which all saw their market caps cross the trillion-dollar mark in recent years. Valued at $280 billion, Salesforce would still need to nearly quadruple its market cap to join the four-comma club.That might sound like a lofty goal, but Salesforce was only worth $ ...

Core Viewpoint - David Tepper's Appaloosa fund increased its stake in Alibaba by 159% in Q1 2024, indicating a potential shift in investor sentiment towards the company despite ongoing U.S.-China tensions [1]. Investment Analysis - Tepper's aggressive investment in Alibaba may prompt other investors to reconsider their stance on the stock, especially given his reputation as a seasoned investor [1][3]. - The stock has risen nearly 30% since its 2024 low on January 18, and it currently trades at a P/E ratio of around 20, suggesting it may still be undervalued despite a previous multiple of 10 [3][4]. - Alibaba's net income for fiscal 2024 was 71 billion renminbi ($11 billion), a 9% increase from the previous year, yet the stock trades below its IPO price from nearly a decade ago, making it an attractive option for long-term investors [4]. Risks and Considerations - Alibaba's stock is represented as an American Depositary Receipt (ADR), which carries specific risks, particularly due to past threats of delisting by the SEC and ongoing U.S.-China tensions [2]. - Risk-averse investors are cautioned against following Tepper's lead due to the potential for renewed regulatory scrutiny and geopolitical risks affecting the stock [5].

Core Insights - Arista Networks has experienced significant stock price appreciation over the past five years, with a return of 422% compared to a mere 74% for the S&P 500 [2][3] - The company's revenue has surged by 157% since 2019, indicating strong sales growth that has contributed to the stock's performance [2] - The price-to-sales ratio for Arista has increased from 8.5 to 16.8, reflecting a nearly doubled market valuation for its sales [2] Performance Analysis - An investment of $200 in Arista stock five years ago would have grown to $1,043, showcasing the stock's impressive returns [2] - In contrast, a similar investment in the S&P 500 would have only yielded around $374, highlighting Arista's superior performance [2] - The stock's rapid growth followed a period of stagnation from 2018 to 2021, where the stock price remained flat before experiencing a significant increase [3] Market Dynamics - The surge in Arista's stock price is attributed to rising demand for high-performance computing stocks, particularly those linked to artificial intelligence [3] - The performance of Arista serves as a reminder that patient investors often reap the most rewards, as those who frequently traded the stock may have missed substantial gains [3]

The tech giant just made its latest move to gain supremacy in the artificial intelligence space.The past year or so has been an exciting time to be a Microsoft (MSFT 0.87%) shareholder. The company was quick to recognize that advances in artificial intelligence (AI) would be game-changing, and it made a number of bold moves to position itself at the forefront of this technological shift.Chief among those was the development of Microsoft Copilot, a suite of generative AI tools that integrate seamlessly into ...